Effect of teriparatide use on bone mineral density and spinal fusion: a narrative review of animal models

References

• Rosen CJ, Bilezikian JP. Clinical review 123: anabolic therapy for osteoporosis. J Clin Endocrinol Metab. 2001;86:957–964.
   PubMed Web of Science ®Google Scholar
• Cheng ML, Gupta V. Teriparatide - Indications beyond osteoporosis. Indian J Endocr Metab. 2012;16:343–348.
   PubMedGoogle Scholar
• Hirsch BP, Unnanuntana A, Cunningham ME, et al. The effect of therapies for osteoporosis on spine fusion: a systematic review. Spine J. 2013;13:190–199.
   PubMed Web of Science ®Google Scholar
• Abe Y, Takahata M, Ito M, et al. Enhancement of graft bone healing by intermittent administration of human parathyroid hormone (1–34) in a rat spinal arthrodesis model. Bone. 2007;41:775–785.
   PubMed Web of Science ®Google Scholar
• Iwata A, Kanayama M, Oha F, et al. Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: a retrospective comparative study. BMC Musculoskelet Disord. 2017;18:148.
   PubMed Web of Science ®Google Scholar
• Ohtori S, Inoue G, Orita S, et al. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine. 2013;38:E487–E492.
   PubMed Web of Science ®Google Scholar
• Sugie-Oya A, Takakura A, Takao-Kawabata R, et al. Comparison of treatment effects of teriparatide and the bisphosphonate risedronate in an aged, osteopenic, ovariectomized rat model under various clinical conditions. J Bone Miner Metab. 2016;34:303–314.
   PubMed Web of Science ®Google Scholar
• Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30:312–321.
   PubMed Web of Science ®Google Scholar
• How FORTEO Works For Osteoporosis [Internet]. [cited 2018 Jun 8]. Available from: https://www.forteo.com/about-osteoporosis-medication.
   Google Scholar
• Shen V, Dempster DW, Birchman R, et al. Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J Clin Invest. 1993;91:2479–2487.
   PubMed Web of Science ®Google Scholar
• Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1–34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res. 1999;14:960–968.
   PubMed Web of Science ®Google Scholar
• Sato M, Vahle J, Schmidt A, et al. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology. 2002;143:3230–3242.
   PubMed Web of Science ®Google Scholar
• Alkhiary YM, Gerstenfeld LC, Krall E, et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J. Bone Joint Surg Am. 2005;87:731–741.
   PubMed Web of Science ®Google Scholar
• Komrakova M, Stuermer EK, Werner C, et al. Effect of human parathyroid hormone hPTH (1–34) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats. Bone. 2010;47:480–492.
   PubMed Web of Science ®Google Scholar
• Nagura N, Komatsu J, Iwase H, et al. Effects of the combination of vitamin K and teriparatide on the bone metabolism in ovariectomized rats. Biomed Rep. 2015;3:295–300.
   PubMed Web of Science ®Google Scholar
• Takao-Kawabata R, Isogai Y, Takakura A, et al. Three-times-weekly administration of teriparatide improves vertebral and peripheral bone density, microarchitecture, and mechanical properties without accelerating bone resorption in ovariectomized rats. Calcif Tissue Int. 2015;97:156–168.
   PubMed Web of Science ®Google Scholar
• Qiu Z, Wei L, Liu J, et al. Effect of intermittent PTH (1–34) on posterolateral spinal fusion with iliac crest bone graft in an ovariectomized rat model. Osteoporos Int. 2013;24:2693–2700.
   PubMed Web of Science ®Google Scholar
• O’Loughlin PF, Cunningham ME, Bukata SV, et al. Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. Spine. 2009;34:121–130.
   PubMed Web of Science ®Google Scholar
• Lehman RA Jr, Dmitriev AE, Cardoso MJ, et al. Effect of teriparatide [rhPTH(1,34)] and calcitonin on intertransverse process fusion in a rabbit model. Spine. 2010;35:146–152.
   PubMed Web of Science ®Google Scholar
• Ming N, Cheng JT-Y, Rui Y-F, et al. Dose-dependent enhancement of spinal fusion in rats with teriparatide (PTH[1-34]) ]). Spine. 2012;37:1275–1282.
   PubMed Web of Science ®Google Scholar
• Lina IA, Puvanesarajah V, Liauw JA, et al. Quantitative study of parathyroid hormone (1-34) and bone morphogenetic protein-2 on spinal fusion outcomes in a rabbit model of lumbar dorsolateral intertransverse process arthrodesis. Spine. 2014;39:347–355.
   PubMed Web of Science ®Google Scholar
• Morimoto T, Kaito T, Kashii M, et al. Effect of intermittent administration of teriparatide (Parathyroid Hormone 1-34) on bone morphogenetic protein-induced bone formation in a rat model of spinal fusion. J. Bone Joint Surg. Am. 2014;96:e107.
   PubMedGoogle Scholar
• Sugiura T, Kashii M, Matsuo Y, et al. Intermittent administration of teriparatide enhances graft bone healing and accelerates spinal fusion in rats with glucocorticoid-induced osteoporosis. Spine J. 2015;15:298–306.
   PubMed Web of Science ®Google Scholar
• Lawrence JP, Ennis F, White AP, et al. Effect of daily parathyroid hormone (1-34) on lumbar fusion in a rat model. Spine J. 2006;6:385–390.
   PubMedGoogle Scholar
• Ohtori S, Inoue G, Orita S, et al. Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study. Spine. 2012;37:E1464–E1468.
   PubMed Web of Science ®Google Scholar
• Hadji P, Zanchetta JR, Russo L, et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2012;23:2141–2150.
   PubMed Web of Science ®Google Scholar
• Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012;27:2429–2437.
   PubMed Web of Science ®Google Scholar